bearish
Giant Biogene Holding (2367.HK) - The Situation May Not Be as Rosy as It Looks
456 Views17 Mar 2023 08:55
After Giant Biogene has been added to Hong Kong Stock Connect, liquidity would improve a lot. But lower-than-expected market space, competition and concerns on business model make outlook challenging.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Healthcare Weekly (Mar.17) - VBP on ICL/Sports Medicine, New Payment System, Time to Long CXO?19 Mar 2023
- Pre-IPO Giant Biogene (2367 HK) - Some Unstable Factors26 Oct 2022
- Bloomage Biotechnology (688363.CH) - Positioning and Strategic Layout Imply Strong Upside Potential17 Oct 2022
- Bloomage Biotechnology (688363.CH) Vs Imeik Technology (300896.CH) - The Logic and the Outlook11 Jan 2022
x